Skip to main content

Bruker Leads Index Again

For the second week in a row, Bruker BioSciences led all gainers in the BCW Index with an increase of 10.8 percent for the five-day trading week ended Tuesday. Last Wednesday, the firm was mentioned in an article on the influential investment website The Motley Fool spotlighting companies with a high percentage of inside stock holders.
 
Bruker’s gains follow last week’s rise of 9.1 percent.
 
Shares of only five companies in the Index lost value for the week. Beckman Coulter and Bio-Rad Laboratories were the only two to lose more than 1 percent, with their shares dropping 1.34 and 1.26 percent, respectively.
 

Overall, the Index gained 2.57 percent for the tracking period. In comparison, the Dow Jones Industrial Average rose 3.2 percent, the Nasdaq gained 2.1 percent, and the Nasdaq Biotech Index increased .7 percent. The stock market received a major boost on Tuesday, when the Federal Reserve cut a key interest rate by .5 percent.

 
 
BioCommerce Week Index of Diversified
Molecular Biology Tool Companies
Company
Ticker
Closing Price
(Sept. 18, 2007)
Starting Price
(Sept. 11, 2007)
% change
Affymetrix
AFFX
24.00
23.41
2.52
Agilent
A
37.20
36.31
2.45
Applied Biosystems
ABI
33.95
32.10
5.76
Beckman
BEC
71.28
72.25
-1.34
Becton Dickinson
BDX
79.25
77.71
1.98
Bio-Rad
BIO
84.48
85.56
-1.26
Bruker
BRKR
8.51
7.68
10.81
Caliper
CALP
5.62
5.41
3.88
Cepheid
CPHD
20.83
20.01
4.10
Illumina
ILMN
53.47
51.43
3.97
Invitrogen
IVGN
81.50
81.52
-0.02
Luminex
LMNX
15.59
14.99
4.00
MDS
MDZ
21.48
20.69
3.82
Millipore
MIL
76.53
73.63
3.94
PerkinElmer
PKI
28.59
27.42
4.27
Qiagen
QGEN
17.09
17.11
-0.12
Sequenom
SQNM
5.00
5.05
-0.99
Sigma-Aldrich
SIAL
46.74
43.86
6.57
Thermo
TMO
57.51
54.50
5.52
Third Wave
TWTI
8.43
8.11
3.95
Waters
WAT
66.46
63.62
4.46
BCW Index Average
40.17
39.16
2.57
The Scan

US Supports Patent Waiver

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.